Palisade bio, inc.PALI.US Overview
US StockHealthcare
(No presentation for PALI)
PALI Overall Performance
PALI AI Analysis & Strategy
PALI Recent Performance
8.15%
Palisade bio, inc.
0.81%
Avg of Sector
-1.14%
S&P500
PALI PowerScanner
PALI Key Information
PALI Valuation Metrics
PALI Earnings Table
PALI Profile
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.